IRWD Klasa A Ironwood Pharmaceuticals, Inc. - Class A Common Stock
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 6, 2026
$3,64
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$1,4152tyg. minimum
$5,7852tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$601M
P/E (TTM)
4.7
EPS (TTM)
$0.77
Przychody (TTM)
$389M
Twoje odznaki
Zakres 52 tyg.
$1–$6
Ocena Analityków
BUY
Cena Docelowa
$6
P/E
4.7
ROE
-55.3%
Marża Zysku Netto
33.4%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
IRWD Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$3.64
Kapitalizacja Rynkowa (MRQ)
$601M
P/E (TTM)
4.7
EPS (TTM)
$0.77
Przychody (TTM)
$389M
ROE (TTM)
-55.3%
Zakres 52 tyg.
$1–$6
IRWD Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
Podziały akcji
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 2 kwietnia 2019 | 597-for-500 | Naprzód |
O Ironwood Pharmaceuticals, Inc. - Class A Common Stock Przegląd firmy z Wikipedii
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler's diarrhea.
By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. By 2006 Microbia was starting to struggle with the different challenges and expenses of drug development, along with its industrial fermentation business and drug discovery efforts, and made the decision to split in two, with "Microbia Precision Engineering" focused on industrial applications led by Bailey and Microbia focused on drug discovery and development. Tate & Lyle invested $7M in the Microbia spinout and took a board seat in 2006. Microbia changed its name to Ironwood in 2008 and shortened the name of the industrial business to Microbia.
By 2009, Ironwood had raised a total of $281M. In early 2010 Ironwood held its IPO, which priced at $11.25 a share, below the target price of $14. Later that year it sold its interests in Microbia to DSM for an undisclosed sum.
Linaclotide (Linzess in the US and Mexico, and as Constella elsewhere), a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause, was approved in the US and Europe in 2012. Most of the marketing rights were licensed to Allergan and Astellas.
It was developing a drug called IW-9179 or recanaclotide but abandoned it in 2016.
Soclenicant (BNC-210; IW-2143) is an anxiolytic that Ironwood licensed and performed R&D on and then abandoned.
In April 2018, the shares of Ironwood Pharmaceuticals closed up more than 10 percent on the news of biotech activist investor, Alex Denner joining its board.
Despite having a billion dollar drug in Linzess, Ironwood - through a series of confounding decisions by management - has seen its stock price crater from a high of $21.16 on July 17, 2018, to its current price of 77 CENTS at the close of trading on August 1, 2025.
== References ==
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaBiotechnology
pracownicy100
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$296M2016-12-31 → 2025-12-31
EPS$0.152018-12-31 → 2025-12-31
Wolny przepływ pieniężny$127M2016-12-31 → 2025-12-31
Marża netto33.4%2018-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | IRWD | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 4.7średnia z 5 lat ≈96.0 | ≈96.0 | · | · | |
| P/S (TTM) | 1.5średnia z 5 lat ≈3.4 | ≈3.4 | 3.9 | Niedowartościowany | |
| P/B (MRQ) | -3.7średnia z 5 lat ≈-0.7 | ≈-0.7 | · | · | |
| Price / FCF (Cena / FCF) | 4.7średnia z 5 lat ≈7.0 | ≈7.0 | · | · | |
| Price / Cash Flow (Cena / Przepływy pieniężne) | 4.7średnia z 5 lat ≈7.0 | ≈7.0 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | -3.7 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | IRWD | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 60.1%średnia z 5 lat ≈-7.3% | ≈-7.3% | -81.6% | Najwyższa półka | |
| EBITDA Margin (Marża EBITDA) | 33.6%średnia z 5 lat ≈-7.0% | ≈-7.0% | -81.6% | Najwyższa półka | |
| Marża przed opodatkowaniem (TTM) | 53.3%średnia z 5 lat ≈-12.4% | ≈-12.4% | -56.0% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | 33.4%średnia z 5 lat ≈-9.5% | ≈-9.5% | -86.5% | Najwyższa półka | |
| ROA (TTM) | 41.4%średnia z 5 lat ≈-8.5% | ≈-8.5% | -53.6% | Najwyższa półka | |
| ROE (TTM) | -55.3%średnia z 5 lat ≈-107.8% | ≈-107.8% | -68.2% | Najwyższa półka | |
| ROIC | -12.9%średnia z 5 lat ≈82.3% | ≈82.3% | 2.1% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | IRWD | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Wskaźnik bieżący (MRQ) | 6.1średnia z 5 lat ≈8.4 | ≈8.4 | 11.4 | Poniżej średniej | |
| Quick Ratio (Wskaźnik Szybkości) | 1.1średnia z 5 lat ≈8.2 | ≈8.2 | 4.0 | Silna płynność |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | IRWD | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | -15.7%średnia z 5 lat ≈-4.6% | ≈-4.6% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | -10.3%średnia z 5 lat ≈-3.8% | ≈-3.8% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | -5.3% | · | · | · | |
| EPS YoY | 1400.0%średnia z 5 lat ≈572.1% | ≈572.1% | · | · | |
| Net Income YoY (Zysk Netto R/R) | 2629.2%średnia z 5 lat ≈986.7% | ≈986.7% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | -46.1% | · | · | · | |
| EPS CAGR 5Y (CAGR z EPS 5 lat) | -25.7% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | -48.4% | · | · | · | |
| Net Income CAGR 5Y (CAGR z zysku netto 5 lat) | -25.7% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | IRWD | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.8średnia z 5 lat ≈0.6 | ≈0.6 | 0.2 | Najwyższa półka | |
| Receivables Turnover (Rotacja należności) | 4.6średnia z 5 lat ≈3.7 | ≈3.7 | · | · | |
| Revenue / Employee (Przychody / pracownika) | ≈$3.0M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-5.1%
Następny raport
Lis 09, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 6, 2026 | $0.31 | $0.36 | -14.6% |
| 31 marca 2026 | $0.24 | $0.24 | -2.0% | |
| 31 grudnia 2025 | $-0.01 | $0.01 | -198.0% | |
| 30 września 2025 | $0.24 | $0.10 | 135.3% | |
| 30 czerwca 2025 | $0.14 | $0.04 | 243.1% | |
| 31 marca 2025 | $-0.14 | $-0.05 | -194.1% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296M | $351M | $443M | $411M | $414M | $390M | $428M | $347M | $298M | $274M | $150M | $76M | |
| Cost of Revenue | · | · | · | · | · | $3M | $24M | $33M | $19M | $2M | $12.0K | $5M | |
| R&D Expense | $95M | $111M | $116M | $44M | $70M | $88M | $115M | $101M | $88M | $139M | $109M | $102M | |
| SG&A Expense | $82M | $144M | $158M | $116M | $111M | $140M | $172M | $220M | $231M | $173M | $125M | $118M | |
| Operating Expenses | $198M | $258M | $1.39B | $160M | $181M | $247M | $308M | $497M | $314M | $326M | $252M | $246M | |
| Operating Income | $99M | $93M | $-945M | $250M | $232M | $143M | $120M | $-151M | $-15M | $-52M | $-102M | $-169M | |
| Interest Expense | · | · | $22M | $8M | $31M | $29M | $37M | $38M | $36M | $39M | $31M | $21M | |
| Other Non-op | $193.0K | $640.0K | $-3M | $2M | $-32M | $-34M | $-61M | $-43M | $-40M | $-30M | $-41M | $-20M | |
| Pretax Income | $70M | $65M | $-948M | $252M | $201M | $109M | $59M | $-194M | · | · | · | · | |
| Income Tax | $46M | $64M | $83M | $77M | $-328M | $3M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $24M | $880.0K | $-1.00B | $175M | $528M | $106M | $22M | $-282M | $-117M | $-82M | $-143M | · | |
| EPS (Basic) | $0.15 | $0.01 | $-6.45 | $1.13 | $3.26 | $0.67 | $0.14 | $-1.85 | · | · | · | · | |
| EPS (Diluted) | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 | $-1.85 | · | · | · | · | |
| Shares (Basic) | 161,842,000 | 159,083,000 | 155,435,000 | 154,366,000 | 162,245,000 | 159,427,000 | 156,023,000 | 152,634,000 | · | · | · | · | |
| Shares (Diluted) | 162,983,000 | 160,084,000 | 155,435,000 | 186,312,000 | 164,418,000 | 160,655,000 | 156,023,000 | 152,634,000 | · | · | · | · | |
| EBITDA | $100M | $94M | $-944M | $252M | $234M | $145M | $126M | $-233M | · | $-42M | $-90M | $-157M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $215M | $89M | $92M | $656M | $620M | $363M | $177M | $173M | $126M | $54M | $261M | $74M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $96M | $251M | $178M | $174M | |
| Receivables | $47M | $82M | $129M | $115M | $114M | $122M | $11M | $21M | $3M | $933.0K | $3M | $10.0K | |
| Inventory | · | · | · | · | · | · | $648.0K | · | $735.0K | $1M | · | $5M | |
| Prepaid Expense | $12M | $12M | $12M | $8M | $9M | $9M | $11M | $10M | $7M | $9M | $6M | $9M | |
| Current Assets | $274M | $182M | $233M | $781M | $745M | $496M | $307M | $266M | $312M | $380M | $500M | $288M | |
| PP&E (Net) | $3M | $4M | $6M | $6M | $8M | $9M | $12M | $8M | $17M | $21M | $21M | $30M | |
| PP&E (Gross) | $11M | $13M | $14M | $17M | $17M | $21M | $23M | $33M | $86M | $83M | $78M | $83M | |
| Accum. Depreciation | $8M | $8M | $9M | $11M | $10M | $12M | $10M | $26M | $69M | $62M | $57M | $53M | |
| Goodwill | · | · | · | · | · | · | $785.0K | $785.0K | $785.0K | $785.0K | · | · | |
| Intangibles | $2M | $3M | $4M | · | · | · | · | · | $160M | $166M | · | · | |
| Other Non-current Assets | $5M | $6M | $4M | $847.0K | $1M | $943.0K | $790.0K | $89.0K | $870.0K | $1M | $3M | $3M | |
| Total Assets | $397M | $351M | $471M | $1.10B | $1.13B | $559M | $403M | $332M | $606M | $710M | $619M | $329M | |
| Accounts Payable | $3M | $2M | $8M | $483.0K | $935.0K | $661.0K | $4M | $15M | $16M | $18M | $9M | $10M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $38M | $23M | $23M | |
| Short-term Debt | · | · | · | · | · | · | · | $48M | · | · | $25M | $11M | |
| Current Liabilities | $242M | $39M | $276M | $26M | $162M | $32M | $41M | $120M | $66M | $91M | $76M | $61M | |
| Capital Leases | $10M | $12M | $15M | $17M | $18M | $20M | $22M | $158.0K | · | $82.0K | $306.0K | $3M | |
| Other Non-current Liabilities | $22M | $17M | $28M | $10M | $4M | $2M | $734.0K | $3M | $5M | $8M | $10M | · | |
| Total Liabilities | $659M | · | · | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | $199M | $398M | $396M | $454M | $430M | · | · | · | · | $221M | · | |
| Total Debt | · | · | · | · | · | · | · | $48M | · | · | $25M | $11M | |
| Common Stock | $163.0K | $160.0K | $156.0K | $154.0K | $162.0K | $161.0K | $158.0K | $154.0K | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.70B | $-1.70B | $-696M | $-938M | $-1.47B | $-1.57B | $-1.59B | $-1.31B | $-1.19B | $-1.11B | $-967M | |
| AOCI | $-1M | $923.0K | $-3M | · | · | · | · | · | $-79.0K | $-7.0K | $-86.0K | $-19.0K | |
| Stockholders' Equity | $-262M | $-301M | $-346M | $652M | $606M | $63M | $-93M | $-196M | $10M | $67M | $95M | $89M | |
| Liabilities + Equity | $397M | $351M | $471M | $1.10B | $1.13B | $559M | $403M | $332M | $606M | $710M | $619M | $329M | |
| Shares Outstanding | 163,058,316 | 160,205,899 | 156,354,238 | 154,026,949 | 162,036,461 | 160,616,675 | 157,535,962 | 154,414,691 | · | · | · | · |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $6M | $4M | $6M | $10M | $12M | $12M | |
| Stock-based Comp | $17M | $30M | $32M | $27M | $22M | $31M | $31M | $41M | $31M | $29M | $25M | $26M | |
| Deferred Tax | $41M | $68M | $73M | $66M | $-333M | · | · | · | · | · | · | · | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $8M | $6M | $981.0K | · | · | |
| Restructuring | $21M | $3M | $17M | · | $1M | $15M | $4M | $15M | · | · | · | $551.0K | |
| Other Non-cash | $44M | $4M | $1.08B | $5M | $43M | $29M | $-48M | $161M | · | · | · | · | |
| Operating Cash Flow | $127M | $104M | $183M | $274M | $262M | $169M | $11M | $-71M | $-101M | $-26M | $-107M | $-156M | |
| CapEx | $34.0K | $142.0K | $273.0K | $136.0K | $265.0K | $2M | $7M | $351.0K | $3M | $4M | $4M | $4M | |
| Investing Cash Flow | $-34.0K | $-142.0K | $-1.03B | $-136.0K | $-265.0K | $-2M | $-11M | $89M | $151M | $-178M | $-9M | $-57M | |
| Debt Issued | · | · | · | · | · | · | · | · | $146M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | $190M | |
| Stock Repurchased | · | · | · | $126M | $24M | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | · | $-126M | $-24M | · | · | · | · | · | · | $190M | |
| Financing Cash Flow | $216.0K | $-107M | $277M | $-238M | $-5M | $19M | $-1M | $30M | $20M | $-4M | $303M | $211M | |
| Net Change in Cash | $127M | $-4M | $-566M | $36M | $257M | $186M | $-2M | $48M | $71M | $-208M | $187M | · | |
| Taxes Paid | $4M | $8M | $10M | $5M | $3M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | $127M | $103M | $183M | $274M | $262M | $167M | $4M | $-80M | · | $-30M | $-111M | $-159M | |
| Levered FCF | · | · | $160M | $268M | $180M | $138M | · | · | · | · | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 33.3% | 26.5% | -213.5% | 61.0% | 56.1% | 36.7% | 28.0% | -68.9% | · | -18.9% | -68.3% | -221.6% | |
| Net Margin | 8.1% | 0.25% | -226.4% | 42.6% | 127.7% | 27.3% | 5.0% | -81.5% | · | · | · | · | |
| Pretax Margin | 23.6% | 18.6% | -214.1% | 61.5% | 48.5% | 28.0% | · | · | · | · | · | · | |
| EBITDA Margin | 33.6% | 26.8% | -213.3% | 61.3% | 56.5% | 37.3% | 29.3% | -67.2% | · | -15.2% | -60.5% | -205.4% | |
| ROA | 6.4% | 0.21% | -127.5% | 15.7% | 62.7% | 22.1% | 5.9% | -60.2% | · | · | · | · | |
| ROE | -8.5% | -0.27% | -654.9% | 29.9% | 94.6% | 309.8% | -17.5% | 143.5% | · | · | · | · | |
| ROIC | -12.9% | -0.42% | 297.1% | 26.6% | 101.0% | 222.6% | · | · | · | · | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 4.7 | 0.8 | 30.6 | 4.6 | 15.4 | 7.5 | 2.2 | · | 4.2 | 6.5 | 4.8 | |
| Quick Ratio | 1.1 | 4.4 | 0.8 | 30.2 | 4.5 | 15.1 | 4.6 | 1.6 | · | 3.4 | 5.8 | 4.1 | |
| Debt / Equity | · | · | · | · | · | · | · | -0.2 | · | · | 0.3 | 0.1 | |
| Interest Coverage | · | · | -43.7 | 32.9 | 7.5 | 4.8 | 3.3 | -6.3 | · | -1.3 | -3.3 | -8.0 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.9 | 0.6 | 0.4 | 0.5 | 0.8 | 1.2 | 0.7 | · | 0.4 | 0.3 | 0.2 | |
| Inventory Turnover | · | · | · | · | · | · | 34.5 | · | · | 3.5 | · | 1.9 | |
| Receivables Turnover | 4.6 | 3.3 | 3.6 | 3.6 | 3.5 | 5.8 | 26.6 | 28.7 | · | 143.5 | 103.4 | 292.3 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.61 | $-1.88 | $-2.21 | $4.24 | $3.74 | $0.39 | $-0.59 | · | · | · | · | · | |
| Revenue / Share | $1.82 | $2.20 | $2.85 | $2.20 | $2.52 | $2.42 | · | · | · | · | · | · | |
| Cash Flow / Share | $0.78 | $0.65 | $1.18 | $1.47 | $1.59 | $1.05 | · | · | · | · | · | · | |
| Cash / Share | $1.32 | $0.55 | $0.59 | $4.26 | $3.83 | $2.26 | $1.12 | · | · | · | · | · | |
| EPS (TTM) | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 | $0.66 | $0.14 | $-1.85 | $-2.38 | $-2.38 | $-2.38 | $-2.38 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -15.7% | -20.6% | 7.8% | -0.76% | 6.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -10.3% | -5.3% | 4.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -5.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 1400.0% | · | · | -70.1% | 386.4% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -46.1% | -85.4% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -25.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 2629.2% | · | · | -66.9% | 397.7% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -48.4% | -88.1% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -25.7% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $296M | $351M | $443M | $411M | $414M | $390M | $428M | $347M | $298M | $274M | $150M | $76M | |
| Net Income TTM | $24M | $880.0K | $-1.00B | $175M | $528M | $106M | $22M | $-282M | $-117M | $-82M | $-143M | · | |
| Market Cap | $550M | $710M | $1.79B | $1.91B | $1.89B | $1.83B | $2.10B | · | · | · | · | · | |
| P/E | 22.5 | 443.0 | -1.8 | 12.9 | 3.6 | 17.3 | 95.1 | -4.7 | -5.3 | -5.4 | -4.1 | -5.4 | |
| P/S | 1.9 | 2.0 | 4.0 | 4.6 | 4.6 | 4.7 | 4.9 | · | · | · | · | · | |
| P/B | -2.1 | -2.4 | -5.2 | 2.9 | 3.1 | 29.2 | -22.5 | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 2.9 | 3.1 | 29.2 | · | · | · | · | · | · | |
| P / Cash Flow | 4.3 | 6.9 | 9.8 | 7.0 | 7.2 | 10.8 | 195.5 | · | · | · | · | · | |
| P / FCF | 4.3 | 6.9 | 9.8 | 7.0 | 7.2 | 11.0 | 593.0 | · | · | · | · | · | |
| Earnings Yield | 4.5% | 0.23% | -56.4% | 7.8% | 27.5% | 5.8% | 1.1% | -21.3% | -19.0% | -18.6% | -24.5% | -18.6% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113M | $107M | $48M | $122M | $85M | $41M | $91M | $92M | $94M | $75M | $118M | $114M | $107M | $104M | $107M | $109M | |
| R&D Expense | $22M | $22M | $22M | $22M | $23M | $27M | $25M | $30M | $30M | $26M | $36M | $33M | $35M | $13M | $10M | $12M | |
| SG&A Expense | $11M | $12M | $19M | $22M | $17M | $24M | $34M | $36M | $37M | $38M | $39M | $36M | $52M | $31M | $28M | $29M | |
| Operating Expenses | $34M | $34M | $41M | $47M | $40M | $70M | $59M | $66M | $69M | $64M | $80M | $74M | $1.19B | $44M | $39M | $40M | |
| Operating Income | $79M | $73M | $7M | $75M | $45M | $-29M | $31M | $26M | $25M | $11M | $38M | $40M | $-1.08B | $60M | $68M | $68M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $7M | · | $10M | $2M | $2M | · | $2M | |
| Other Non-op | $42.0K | $42.0K | $77.0K | $40.0K | $39.0K | $37.0K | $21M | $-8M | $-6M | $-6M | $-7M | $-8M | $7M | $6M | $4M | $1M | |
| Pretax Income | $74M | $65M | $455.0K | $68M | $38M | $-36M | $24M | $17M | $19M | $5M | $30M | $32M | $-1.08B | $66M | $72M | $70M | |
| Income Tax | $22M | $24M | $3M | $28M | $14M | $1M | $22M | $14M | $20M | $9M | $32M | $18M | $13M | $20M | $23M | $20M | |
| Net Income | $51M | $41M | $-2M | $40M | $24M | $-37M | $2M | $4M | $-860.0K | $-4M | $-1M | $15M | $-1.06B | $46M | $49M | $50M | |
| EPS (Basic) | $0.31 | $0.25 | $-0.01 | $0.25 | $0.15 | $-0.23 | $0.01 | $0.02 | $-0.01 | $-0.03 | $-0.01 | $0.10 | $-6.84 | $0.30 | $0.31 | $0.33 | |
| EPS (Diluted) | $0.31 | $0.24 | $-0.01 | $0.23 | $0.14 | $-0.23 | $0.01 | $0.02 | $-0.01 | $-0.03 | $-0.01 | $0.09 | $-6.84 | $0.25 | $0.26 | $0.28 | |
| Shares (Basic) | 164,405,000 | 163,451,000 | · | 162,215,000 | 161,723,000 | 160,974,000 | · | 159,706,000 | 159,014,000 | 157,700,000 | · | 155,886,000 | 155,367,000 | 154,452,000 | · | 153,066,000 | |
| Shares (Diluted) | 167,179,000 | 166,690,000 | · | 177,764,000 | 176,837,000 | 160,974,000 | · | 160,232,000 | 159,014,000 | 157,700,000 | · | 186,891,000 | 155,367,000 | 186,680,000 | · | 184,465,000 | |
| EBITDA | $79M | $73M | · | $75M | $45M | $-29M | · | $26M | $25M | $11M | · | $40M | $-1.08B | $60M | · | $68M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79M | $220M | $215M | $140M | $93M | $108M | $89M | $88M | $106M | $122M | $92M | $110M | $175M | $740M | $656M | $574M | |
| Receivables | $113M | $106M | $47M | $120M | $86M | $40M | $82M | $76M | $58M | $72M | $129M | $125M | $119M | $116M | · | $117M | |
| Prepaid Expense | $7M | $6M | $12M | $13M | $13M | $12M | $12M | $14M | $15M | $15M | $12M | $18M | $22M | $9M | · | $7M | |
| Current Assets | $199M | $332M | $274M | $274M | $192M | $161M | $182M | $179M | $178M | $208M | $233M | $254M | $318M | $866M | · | $699M | |
| PP&E (Net) | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $11M | · | · | · | $13M | · | · | · | $14M | · | · | · | · | · | |
| Accum. Depreciation | · | · | $8M | · | · | · | $8M | · | · | · | $9M | · | · | · | · | · | |
| Intangibles | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | · | · | · | |
| Other Non-current Assets | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | $4M | $4M | $4M | $820.0K | · | $863.0K | |
| Total Assets | $285M | $435M | $397M | $396M | $343M | $327M | $351M | $390M | $396M | $439M | $471M | $524M | $603M | $1.16B | · | $1.04B | |
| Accounts Payable | $911.0K | $3M | $3M | $2M | $1M | $6M | $2M | $3M | $3M | $6M | $8M | $5M | $4M | $118.0K | · | $795.0K | |
| Current Liabilities | $33M | $236M | $242M | $243M | $233M | $48M | $39M | $49M | $46M | $252M | $276M | $281M | $305M | $24M | · | $27M | |
| Capital Leases | $9M | $9M | $10M | $10M | $11M | $12M | $12M | $13M | $13M | $14M | $15M | $15M | $16M | $16M | · | $17M | |
| Other Non-current Liabilities | $21M | $21M | $22M | $22M | $22M | $17M | $17M | $40M | $35M | $29M | $28M | $31M | $31M | $12M | · | $9M | |
| Total Liabilities | $447M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | $200M | $199M | $199M | · | $199M | $199M | $398M | · | $397M | $397M | $397M | · | $396M | |
| Common Stock | $165.0K | $165.0K | $163.0K | $163.0K | $162.0K | $162.0K | $160.0K | $160.0K | $160.0K | $159.0K | $156.0K | $156.0K | $156.0K | $155.0K | · | $153.0K | |
| Retained Earnings | $-1.58B | $-1.63B | $-1.67B | $-1.67B | $-1.71B | $-1.74B | $-1.70B | $-1.70B | $-1.70B | $-1.70B | $-1.70B | $-1.70B | $-1.71B | $-651M | · | $-745M | |
| AOCI | $-324.0K | $-795.0K | $-1M | $-2M | $-2M | $294.0K | $923.0K | $-2M | $-470.0K | $-922.0K | $-3M | $-752.0K | · | · | · | · | |
| Stockholders' Equity | $-162M | $-217M | $-262M | $-264M | $-308M | $-334M | $-301M | $-311M | $-322M | $-331M | $-346M | $-323M | $-346M | $707M | · | $591M | |
| Liabilities + Equity | $285M | $435M | $397M | $396M | $343M | $327M | $351M | $390M | $396M | $439M | $471M | $524M | $603M | $1.16B | · | $1.04B | |
| Shares Outstanding | 165,239,947 | 164,613,406 | 163,058,316 | 162,678,647 | 162,434,130 | 161,809,432 | 160,205,899 | 160,015,888 | 159,739,001 | 158,957,123 | 156,354,238 | 156,125,676 | 156,027,648 | 155,346,103 | · | 153,319,417 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $8M | $9M | $8M | $9M | $8M | $8M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $20M | $16M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $639.0K | $5M | · | · | · | · | |
| Operating Cash Flow | $58M | $5M | $75M | $48M | $-15M | $20M | $15M | $10M | $33M | $45M | $36M | $32M | $35M | $80M | $79M | $69M | |
| CapEx | · | · | $-1.0K | $2.0K | $2.0K | $31.0K | $0 | $16.0K | $58.0K | $68.0K | $211.0K | $49.0K | $0 | $13.0K | $-27.0K | $66.0K | |
| Investing Cash Flow | · | · | $1.0K | $-2.0K | $-2.0K | $-31.0K | $0 | $-16.0K | $-58.0K | $-68.0K | $-4M | $-23M | $-999M | $-13.0K | $27.0K | $-66.0K | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Financing Cash Flow | · | · | $122.0K | $0 | $88.0K | $6.0K | $-15M | $-27M | $-49M | $-16M | $-51M | $-75M | $399M | $4M | $3M | $797.0K | |
| Net Change in Cash | $-141M | $5M | $75M | $48M | $-16M | $20M | $348.0K | $-17M | $-16M | $29M | $-19M | $-65M | $-565M | $84M | $82M | $70M | |
| Free Cash Flow | · | · | · | · | · | $20M | · | · | · | $45M | · | · | · | $80M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $51M | · | · | · | $79M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 70.2% | 68.1% | · | 61.8% | 53.2% | -70.8% | · | 28.0% | 26.5% | 14.7% | · | 35.2% | -1008.7% | 57.8% | · | 63.0% | |
| Net Margin | 45.4% | 38.3% | · | 32.8% | 27.7% | -90.9% | · | 4.0% | -0.91% | -5.6% | · | 13.5% | -989.2% | 43.9% | · | 46.3% | |
| Pretax Margin | 65.2% | 61.2% | · | 55.7% | 44.4% | -88.2% | · | 19.0% | 20.0% | 6.6% | · | 28.1% | -1002.2% | 63.3% | · | 64.3% | |
| EBITDA Margin | 70.2% | 68.1% | · | 61.8% | 53.2% | -70.8% | · | 28.0% | 26.5% | 14.7% | · | 35.2% | -1008.7% | 57.8% | · | 63.0% | |
| ROA | 16.3% | 10.7% | · | 10.2% | 6.4% | -9.8% | · | 0.80% | -0.17% | -0.52% | · | 2.0% | -131.9% | 4.3% | · | 4.8% | |
| ROE | -21.8% | -14.8% | · | -13.9% | -7.5% | 11.2% | · | -1.1% | 0.26% | -2.2% | · | 11.4% | -1279.3% | 7.4% | · | 8.6% | |
| ROIC | -34.1% | -20.9% | · | -16.8% | -9.2% | 9.0% | · | -1.7% | 0.35% | 2.8% | · | -5.4% | 317.2% | 5.9% | · | 8.3% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.1 | 1.4 | · | 1.1 | 0.8 | 3.3 | · | 3.6 | 3.9 | 0.8 | · | 0.9 | 1.0 | 36.3 | · | 25.8 | |
| Quick Ratio | 5.8 | 1.4 | · | 1.1 | 0.8 | 3.1 | · | 3.3 | 3.6 | 0.8 | · | 0.8 | 1.0 | 35.9 | · | 25.5 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 1.5 | · | 4.1 | -588.7 | 39.4 | · | 44.9 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.1 | 1.5 | · | 1.2 | 1.2 | 0.7 | · | 0.9 | 1.1 | 0.8 | · | 0.9 | 1.0 | 1.0 | · | 1.0 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.98 | $-1.32 | · | $-1.62 | $-1.90 | $-2.06 | · | $-1.95 | $-2.01 | $-2.08 | · | $-2.07 | $-2.22 | $4.55 | · | $3.86 | |
| Revenue / Share | $0.68 | $0.64 | · | $0.69 | $0.48 | $0.26 | · | $0.57 | $0.59 | $0.47 | · | $0.61 | $0.69 | $0.56 | · | $0.59 | |
| Cash Flow / Share | · | $0.03 | · | · | · | $0.12 | · | · | · | $0.29 | · | · | · | $0.43 | · | · | |
| Cash / Share | $0.48 | $1.34 | · | $0.86 | $0.57 | $0.67 | · | $0.55 | $0.66 | $0.76 | · | $0.71 | $1.12 | $4.77 | · | $3.75 | |
| EPS (TTM) | $0.77 | $0.60 | · | $0.15 | $-0.06 | $-0.21 | · | $-0.03 | $0.04 | $-6.79 | · | $-6.24 | $-6.05 | $1.00 | · | $0.93 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $389M | $362M | · | $339M | $309M | $318M | · | $378M | $401M | $414M | · | $432M | $427M | $417M | · | $421M | |
| Net Income TTM | $130M | $102M | · | $29M | $-8M | $-32M | · | $-2M | $9M | $-1.05B | · | $-952M | $-917M | $182M | · | $168M | |
| Market Cap | $696M | $578M | · | $213M | $117M | $238M | · | $659M | $1.04B | $1.38B | · | $1.50B | $1.66B | $1.63B | · | $1.59B | |
| P/E | 5.5 | 5.8 | · | 8.7 | -12.0 | -7.0 | · | -137.3 | 163.0 | -1.3 | · | -1.5 | -1.8 | 10.5 | · | 11.1 | |
| P/S | 1.8 | 1.6 | · | 0.6 | 0.4 | 0.7 | · | 1.7 | 2.6 | 3.3 | · | 3.5 | 3.9 | 3.9 | · | 3.8 | |
| P/B | -4.3 | -2.7 | · | -0.8 | -0.4 | -0.7 | · | -2.1 | -3.2 | -4.2 | · | -4.7 | -4.8 | 2.3 | · | 2.7 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | · | · | 2.3 | · | 2.7 | |
| P / Cash Flow | · | 112.8 | · | · | · | 11.9 | · | · | · | 30.8 | · | · | · | 20.4 | · | · | |
| Earnings Yield | 18.3% | 17.1% | · | 11.5% | -8.3% | -14.3% | · | -0.73% | 0.61% | -78.0% | · | -64.8% | -56.9% | 9.5% | · | 9.0% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $296M | $351M | $443M | $411M | $414M |
| Marża Operacyjna % | 33.3% | 26.5% | -213.5% | 61.0% | 56.1% |
| Zysk netto | $24M | $880.0K | $-1.00B | $175M | $528M |
| Rozwodniony EPS | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 1.1 | 4.7 | 0.8 | 30.6 | 4.6 |
| Wskaźnik Szybkości | 1.1 | 4.4 | 0.8 | 30.2 | 4.5 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $127M | $103M | $183M | $274M | $262M |
Właściciele instytucjonalni (13F) 229 emitentów · $708.7M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
229
Wartość posiadanych akcji
$708.7M
Nowe pozycje
25
Zamknięte pozycje
32
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 25 (-35 vs poprzedni kw.) | 32 (+7 vs poprzedni kw.) | 75 (-11 vs poprzedni kw.) | 85 (+30 vs poprzedni kw.) | -11.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $74 889 826 | 17 788 557 | 10,57% | Akcje |
| ARMISTICE CAPITAL, LLC | $58 653 720 | 13 932 000 | 8,28% | Akcje |
| VANGUARD GROUP INC | $53 779 120 | 15 958 196 | 7,59% | Akcje |
| Sarissa Capital Management LP | $38 684 153 | 9 188 635 | 5,46% | Akcje |
| STATE STREET CORP | $37 088 420 | 8 809 601 | 5,23% | Akcje |
| BANK OF AMERICA CORP /DE/ | $36 558 810 | 8 683 803 | 5,16% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $33 651 481 | 7 993 226 | 4,75% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $27 821 819 | 6 608 508 | 3,93% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $27 221 528 | 6 465 921 | 3,84% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $23 211 225 | 5 513 355 | 3,28% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $20 345 036 | 4 831 657 | 2,87% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $19 181 135 | 4 556 089 | 2,71% | Akcje |
| MARSHALL WACE, LLP | $18 061 293 | 4 290 093 | 2,55% | Akcje |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $17 117 708 | 4 065 964 | 2,42% | Akcje |
| GOLDMAN SACHS GROUP INC | $13 951 132 | 3 313 808 | 1,97% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $13 902 439 | 3 302 242 | 1,96% | Akcje |
| FEDERATED HERMES, INC. | $13 603 512 | 3 231 238 | 1,92% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $12 701 945 | 3 017 089 | 1,79% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $10 622 431 | 2 522 891 | 1,50% | Akcje |
| TWO SIGMA ADVISERS, LP | $10 582 137 | 3 140 100 | 1,49% | Akcje |
| MACKENZIE FINANCIAL CORP | $9 967 146 | 2 367 493 | 1,41% | Akcje |
| MORGAN STANLEY | $7 830 240 | 1 859 914 | 1,10% | Akcje |
| Connor, Clark & Lunn Investment Management Ltd. | $7 627 316 | 1 811 714 | 1,08% | Akcje |
| NORTHERN TRUST CORP | $5 784 430 | 1 373 974 | 0,82% | Akcje |
| Hillsdale Investment Management Inc. | $5 264 302 | 1 250 428 | 0,74% | Akcje |
| WELLS FARGO & COMPANY/MN | $5 078 094 | 1 206 198 | 0,72% | Akcje |
| DEUTSCHE BANK AG\ | $4 875 761 | 1 158 138 | 0,69% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $4 379 810 | 1 040 335 | 0,62% | Akcje |
| FRANKLIN RESOURCES INC | $4 239 382 | 1 006 979 | 0,60% | Akcje |
| FMR LLC | $3 828 942 | 909 488 | 0,54% | Akcje |
| STATE OF WISCONSIN INVESTMENT BOARD | $3 277 548 | 778 515 | 0,46% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $3 052 608 | 725 085 | 0,43% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $2 772 104 | 658 457 | 0,39% | Akcje |
| IEQ CAPITAL, LLC | $2 364 286 | 561 588 | 0,33% | Akcje |
| Vanguard Global Advisers, LLC | $2 361 970 | 561 038 | 0,33% | Akcje |
| PRUDENTIAL FINANCIAL INC | $2 261 608 | 537 199 | 0,32% | Akcje |
| Bank of New York Mellon Corp | $2 142 384 | 508 880 | 0,30% | Akcje |
| CITADEL ADVISORS LLC | $2 115 117 | 502 403 | 0,30% | Akcje |
| VOYA INVESTMENT MANAGEMENT LLC | $2 039 535 | 484 450 | 0,29% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $1 973 737 | 468 821 | 0,28% | Akcje |
| SEI INVESTMENTS CO | $1 934 150 | 459 417 | 0,27% | Akcje |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $1 897 127 | 540 492 | 0,27% | Akcje |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $1 847 815 | 438 911 | 0,26% | Akcje |
| Inspire Investing, LLC | $1 789 893 | 509 941 | 0,25% | Akcje |
| SEGALL BRYANT & HAMILL, LLC | $1 717 949 | 408 064 | 0,24% | Akcje |
| Invesco Ltd. | $1 697 510 | 403 209 | 0,24% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 670 528 | 396 800 | 0,24% | Opcja sprzedaży |
| Man Group plc | $1 650 813 | 392 117 | 0,23% | Akcje |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $1 641 029 | 389 793 | 0,23% | Akcje |
| UBS Group AG | $1 639 917 | 389 529 | 0,23% | Akcje |
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Sarissa Capital Management LP, Alexander J. Denner | 19 marca 2026 | 5,80% | Aneks | · | SEC |
| Ironwood Pharmaceuticals, Inc. | 7 lipca 2023 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| OR ×3 zgłoszenia | 1 marca 2021 | · | Pierwotne zgłoszenie | · | SEC |
| 9 listopada 2020 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 41 insiderów · 18 dyrektorzy generalni · 22 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Thomas A Mccourt | Chief Executive Officer | 10 marca 2026 A | 1 898 838 | 0 | 2 | $-739 929 |
| Mark Mallon | Chief Executive Officer | 26 lutego 2021 S | 470 605 | 0 | 0 | $0 |
| Peter M. Hecht | Chief Executive Officer | 1 kwietnia 2019 D | 2 217 366 | 0 | 0 | $0 |
| Gregory S. Martini | Chief Financial Officer | 10 marca 2026 A | 297 213 | 0 | 2 | $-81 888 |
| Sravan Kumar Emany | SVP, COO and CFO | 18 listopada 2024 S | 309 572 | 0 | 0 | $0 |
| Gina Consylman | SVP, CFO & Treasurer | 26 marca 2021 A | 392 616 | 0 | 0 | $0 |
| Jason Rickard | SVP, Chief Operating Officer | 8 marca 2023 A | 376 316 | 0 | 0 | $0 |
| William Huyett | Chief Operating Officer | 1 kwietnia 2019 D | 27 546 | 0 | 0 | $0 |
| Michael J Higgins | Chief Operating Officer | 23 grudnia 2014 M | 329 102 | 0 | 0 | $0 |
| Jeffrey Silber | SVP, CMO, Head-Res&Drug | 20 lipca 2026 A | 137 036 | 0 | 0 | $0 |
| Ronald Silver | PFO & PAO | 7 lipca 2026 S | 313 680 | 0 | 4 | $-831 183 |
| Tammi L Gaskins | Chief Commercial Officer | 10 marca 2026 A | 350 350 | 0 | 3 | $-100 301 |
| Minardo John | Chief Legal Officer | 10 marca 2026 A | 500 498 | 0 | 2 | $-136 177 |
| Michael Shetzline | SVP, CMO, Head-Res&Drug | 10 marca 2026 A | 658 037 | 0 | 2 | $-121 586 |
| Andrew Davis | SVP, Chief Business Officer | 18 listopada 2024 S | 284 685 | 0 | 0 | $0 |
| Conor Kilroy | SVP, GC & Secretary | 26 lutego 2021 S | 122 336 | 0 | 0 | $0 |
| Kelly Macdonald | Chief Accounting Officer | 4 grudnia 2020 M | 93 041 | 0 | 0 | $0 |
| Halley E Gilbert | Chief Admin Officer & SVP | 21 lutego 2020 S | 265 991 | 0 | 0 | $0 |
| DENNER ALEXANDER J | Dyrektor | 15 września 2026 A | 327 549 | 0 | 2 | $-20 530 448 |
| Catherine Moukheibir | Dyrektor | 16 czerwca 2026 A | 181 425 | 0 | 0 | $0 |
| Jon R Duane | Dyrektor | 16 czerwca 2026 A | 253 820 | 0 | 0 | $0 |
| Marla L Kessler | Dyrektor | 16 czerwca 2026 A | 229 364 | 0 | 0 | $0 |
| Jay Shepard | Dyrektor | 16 czerwca 2026 A | 235 036 | 0 | 0 | $0 |
| Julie Mchugh | Dyrektor | 16 czerwca 2026 S | 250 749 | 0 | 1 | $-80 460 |
| Mark G Currie | Dyrektor | 16 czerwca 2026 A | 676 900 | 0 | 0 | $0 |
| Andrew Dreyfus | Dyrektor | 10 czerwca 2025 A | 228 313 | 0 | 0 | $0 |
| Edward P Owens | Dyrektor | 2 czerwca 2021 A | 241 720 | 0 | 0 | $0 |
| Lawrence S Olanoff | Dyrektor | 2 czerwca 2021 A | 91 395 | 0 | 0 | $0 |
| Amy Schulman | Dyrektor | 1 kwietnia 2019 D | 38 242 | 0 | 0 | $0 |
| Marsha Fanucci | Dyrektor | 1 kwietnia 2019 D | 132 663 | 0 | 0 | $0 |
| Douglas E Williams | Dyrektor | 1 kwietnia 2019 D | 87 800 | 0 | 0 | $0 |
| Terrance McGuire | Dyrektor | 1 kwietnia 2019 D | 73 630 | 0 | 0 | $0 |
| WALSH CHRISTOPHER T PHD | Dyrektor | 15 marca 2017 A | 71 499 | 0 | 0 | $0 |
| George N Conrades | Dyrektor | 3 czerwca 2015 A | 62 221 | 0 | 0 | $0 |
| David A Ebersman | Dyrektor | 13 marca 2015 A | 29 714 | 0 | 0 | $0 |
| COOK JOSEPH C JR | Dyrektor | 12 marca 2015 S | 304 080 | 0 | 0 | $0 |
| David Evans Shaw | Dyrektor | 14 marca 2014 A | 64 306 | 0 | 0 | $0 |
| VR Management LLC | Posiadacz 10% | 15 stycznia 2013 J | 2 442 | 0 | 0 | $0 |
| FMR LLC | Posiadacz 10% | 10 lipca 2012 S | 2 340 891 | 0 | 0 | $0 |
| Thomas Graney | · | 27 lutego 2017 A | 42 013 | 0 | 0 | $0 |
| Bryan E Roberts | · | 15 czerwca 2015 A | 31 951 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 33 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,60% | 371 823 NS | 31 lipca 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,48% | 28 214 SH | 1 października 2026 | Dziennie |
| LABU · Direxion Shares ETF Trust | 0,16% | 186 886 NS | 31 lipca 2026 | N-PORT |
| IWC · iShares Trust | 0,15% | 554 146 SH | 11 września 2026 | Dziennie |
| VFVA · VANGUARD WELLINGTON FUND | 0,13% | 267 285 SH | 19 sierpnia 2026 | Dziennie |
| CALF · Pacer Funds Trust | 0,12% | 1 079 411 NS | 31 lipca 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,11% | 521 040 SH | 19 sierpnia 2026 | Dziennie |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0,10% | 135 991 NS | 31 lipca 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 466 785 NS | 31 lipca 2026 | N-PORT |
| IBB · iShares Trust | 0,05% | 1 214 535 SH | 11 września 2026 | Dziennie |
| PWS · Pacer Funds Trust | 0,04% | 2 553 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,04% | 11 684 SH | 1 października 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,04% | 287 297 SH | 1 października 2026 | Dziennie |
| IWO · iShares Trust | 0,04% | 1 446 914 SH | 11 września 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 165 563 SH | 19 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,02% | 78 252 NS | 31 lipca 2026 | N-PORT |
| IWM · iShares Trust | 0,02% | 4 241 422 SH | 11 września 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 943 404 SH | 19 sierpnia 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,01% | 534 999 NS | 31 lipca 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1 677 357 SH | 19 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,01% | 437 643 SH | 19 sierpnia 2026 | Dziennie |
| DFAC · Dimensional ETF Trust | 0,00% | 272 518 NS | 31 lipca 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,00% | 8 700 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 11 833 NS | 31 lipca 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 197 587 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,00% | 41 467 SH | 9 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,00% | 32 200 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 11 941 NS | 31 lipca 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4 781 484 SH | 19 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9 494 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13 354 SH | 19 sierpnia 2026 | Dziennie |
| IWN · iShares Trust | · | 92 403 SH | 11 września 2026 | Dziennie |
| SMLF · iShares Trust | · | 383 496 SH | 11 września 2026 | Dziennie |
IRWD Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 10 analityków
KUP
Średni cel
$5.35
+47,0%
2 20,0%
Mocne kupno
5 50,0%
Kup
3 30,0%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
4 analityków · 2026-09-30Średnia cel $6.10 +67,6%
← Poniżej wszystkich celów
Aktualna cena $3.64
Niski$3.70
Średnia$6.10
Wysoki$10.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| IRWD | $550M | 22.5 | -15.7% | 8.1% | -8.5% | · |
| STTK | $231M | -5.2 | -82.5% | -4880.9% | -70.0% | · |
| MDXG | $1.00B | 21.2 | 20.0% | 11.6% | 20.5% | 82.6% |
| AURA | $347M | -3.1 | -29.7% | -1601.4% | -68.2% | · |
| CLYM | $191M | -4.5 | · | · | -34.6% | · |
| CTMX | $725M | · | -44.8% | -22.8% | -15.9% | · |
| SGMT | · | -3.7 | · | · | -42.3% | · |
| MPLT | $773M | -0.9 | · | · | -151.1% | · |
| PRME | $626M | -2.6 | 55.3% | -4342.4% | -221.4% | · |
| ALT | $400M | -3.6 | 105.0% | -214861.0% | -45.6% | · |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 6, 2026